BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 11438506)

  • 21. Hepatocellular bile acid transport and ursodeoxycholic acid hypercholeresis.
    Scharschmidt BF; Lake JR
    Dig Dis Sci; 1989 Dec; 34(12 Suppl):5S-15S. PubMed ID: 2689116
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Regulation of hepatic transport systems involved in bile secretion during liver regeneration in rats.
    Vos TA; Ros JE; Havinga R; Moshage H; Kuipers F; Jansen PL; Müller M
    Hepatology; 1999 Jun; 29(6):1833-9. PubMed ID: 10347127
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CAR and PXR agonists stimulate hepatic bile acid and bilirubin detoxification and elimination pathways in mice.
    Wagner M; Halilbasic E; Marschall HU; Zollner G; Fickert P; Langner C; Zatloukal K; Denk H; Trauner M
    Hepatology; 2005 Aug; 42(2):420-30. PubMed ID: 15986414
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Conjugation is essential for the anticholestatic effect of NorUrsodeoxycholic acid in taurolithocholic acid-induced cholestasis in rat liver.
    Denk GU; Maitz S; Wimmer R; Rust C; Invernizzi P; Ferdinandusse S; Kulik W; Fuchsbichler A; Fickert P; Trauner M; Hofmann AF; Beuers U
    Hepatology; 2010 Nov; 52(5):1758-68. PubMed ID: 21038414
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cytotoxicity of bile salts against biliary epithelium: a study in isolated bile ductule fragments and isolated perfused rat liver.
    Benedetti A; Alvaro D; Bassotti C; Gigliozzi A; Ferretti G; La Rosa T; Di Sario A; Baiocchi L; Jezequel AM
    Hepatology; 1997 Jul; 26(1):9-21. PubMed ID: 9214446
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Metabolism and effects on cholestasis of isoursodeoxycholic and ursodeoxycholic acids in bile duct ligated rats.
    Purucker E; Marschall HU; Winograd R; Matern S
    Biochim Biophys Acta; 2001 Apr; 1526(1):44-52. PubMed ID: 11287121
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bile acid supplementation improves established liver steatosis in obese mice independently of glucagon-like peptide-1 secretion.
    Quintero P; Pizarro M; Solís N; Arab JP; Padilla O; Riquelme A; Arrese M
    J Physiol Biochem; 2014 Sep; 70(3):667-74. PubMed ID: 24816727
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lessons from the toxic bile concept for the pathogenesis and treatment of cholestatic liver diseases.
    Trauner M; Fickert P; Halilbasic E; Moustafa T
    Wien Med Wochenschr; 2008; 158(19-20):542-8. PubMed ID: 18998069
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Regulation of alkaline phosphatase gene expression in human hepatoma cells by bile acids.
    Khan KN; Tsutsumi T; Nakata K; Nakao K; Kato Y; Nagataki S
    J Gastroenterol Hepatol; 1998 Jun; 13(6):643-50. PubMed ID: 9715409
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Geniposide attenuates ANIT-induced cholestasis through regulation of transporters and enzymes involved in bile acids homeostasis in rats.
    Wang L; Wu G; Wu F; Jiang N; Lin Y
    J Ethnopharmacol; 2017 Jan; 196():178-185. PubMed ID: 27988401
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ursodeoxycholic acid (UDCA) prevents DCA effects on male mouse liver via up-regulation of CYP [correction of CXP] and preservation of BSEP activities.
    Paolini M; Pozzetti L; Montagnani M; Potenza G; Sabatini L; Antelli A; Cantelli-Forti G; Roda A
    Hepatology; 2002 Aug; 36(2):305-14. PubMed ID: 12143038
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ursodeoxycholic acid inhibits hepatic cystogenesis in experimental models of polycystic liver disease.
    Munoz-Garrido P; Marin JJ; Perugorria MJ; Urribarri AD; Erice O; Sáez E; Úriz M; Sarvide S; Portu A; Concepcion AR; Romero MR; Monte MJ; Santos-Laso Á; Hijona E; Jimenez-Agüero R; Marzioni M; Beuers U; Masyuk TV; LaRusso NF; Prieto J; Bujanda L; Drenth JP; Banales JM
    J Hepatol; 2015 Oct; 63(4):952-61. PubMed ID: 26044126
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cytokeratins as targets for bile acid-induced toxicity.
    Fickert P; Trauner M; Fuchsbichler A; Stumptner C; Zatloukal K; Denk H
    Am J Pathol; 2002 Feb; 160(2):491-9. PubMed ID: 11839569
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Induction of short heterodimer partner 1 precedes downregulation of Ntcp in bile duct-ligated mice.
    Zollner G; Fickert P; Silbert D; Fuchsbichler A; Stumptner C; Zatloukal K; Denk H; Trauner M
    Am J Physiol Gastrointest Liver Physiol; 2002 Jan; 282(1):G184-91. PubMed ID: 11751172
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Low retinol levels differentially modulate bile salt-induced expression of human and mouse hepatic bile salt transporters.
    Hoeke MO; Plass JR; Heegsma J; Geuken M; van Rijsbergen D; Baller JF; Kuipers F; Moshage H; Jansen PL; Faber KN
    Hepatology; 2009 Jan; 49(1):151-9. PubMed ID: 19111018
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Regulation of drug transporters by the farnesoid X receptor in mice.
    Maeda T; Miyata M; Yotsumoto T; Kobayashi D; Nozawa T; Toyama K; Gonzalez FJ; Yamazoe Y; Tamai I
    Mol Pharm; 2004; 1(4):281-9. PubMed ID: 15981587
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 3alpha-6alpha-Dihydroxy-7alpha-fluoro-5beta-cholanoate (UPF-680), physicochemical and physiological properties of a new fluorinated bile acid that prevents 17alpha-ethynyl-estradiol-induced cholestasis in rats.
    Clerici C; Castellani D; Asciutti S; Pellicciari R; Setchell KD; O'Connell NC; Sadeghpour B; Camaioni E; Fiorucci S; Renga B; Nardi E; Sabatino G; Clementi M; Giuliano V; Baldoni M; Orlandi S; Mazzocchi A; Morelli A; Morelli O
    Toxicol Appl Pharmacol; 2006 Jul; 214(2):199-208. PubMed ID: 16487557
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intestinal absorption and biliary secretion of ursodeoxycholic acid and its taurine conjugate.
    Rudolph G; Kloeters-Plachky P; Sauer P; Stiehl A
    Eur J Clin Invest; 2002 Aug; 32(8):575-80. PubMed ID: 12190957
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hepatobiliary transport.
    Kullak-Ublick GA; Beuers U; Paumgartner G
    J Hepatol; 2000; 32(1 Suppl):3-18. PubMed ID: 10728790
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cholic acid and ursodeoxycholic acid therapy in primary biliary cirrhosis. Changes in bile acid patterns and their correlation with liver function.
    Güldütuna S; Leuschner M; Wunderlich N; Nickel A; Bhatti S; Hübner K; Leuschner U
    Eur J Clin Pharmacol; 1993; 45(3):221-5. PubMed ID: 8276045
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.